Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study

Gynecologic Oncology ◽

Oncology Group ◽

Ancillary Data ◽

Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.07.020 ◽

2019 ◽

Vol 155 (1) ◽

pp. 69-74 ◽

Cited By ~ 1

Author(s):

K.N. Slaughter Wade ◽

M.F. Brady ◽

T. Thai ◽

Y. Wang ◽

B. Zheng ◽

...

Keyword(s):

Ovarian Cancer ◽

Data Analysis ◽

Gynecologic Oncology ◽

Prognostic Biomarkers ◽

Oncology Group ◽

Ancillary Data

Association between quality of life and clinical outcome in women with advanced epithelial ovarian cancer receiving chemotherapy with concurrent and maintenance bevacizumab: Results from a prospective multicenter phase III NRG Oncology/Gynecologic Oncology Group (GOG) trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.04.019 ◽

2015 ◽

Vol 138 ◽

pp. 2

Author(s):

N.T. Phippen ◽

B.A. Davidson ◽

S. Wolf ◽

G. Samsa ◽

D. Cella ◽

...

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Clinical Outcome ◽

Gynecologic Oncology ◽

Phase Iii ◽

Oncology Group ◽

Multicenter Phase ◽

Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.5026 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5026-5026

Author(s):

L. B. Wenzel ◽

H. Huang ◽

D. Armstrong ◽

J. Walker ◽

D. Cella

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Gynecologic Oncology ◽

Randomized Study ◽

Stage Iii ◽

Oncology Group ◽

Group Trial

Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.5026 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5026-5026 ◽

Cited By ~ 4

Author(s):

L. B. Wenzel ◽

H. Huang ◽

D. Armstrong ◽

J. Walker ◽

D. Cella

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Gynecologic Oncology ◽

Randomized Study ◽

Stage Iii ◽

Oncology Group ◽

Group Trial

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.11.018 ◽

2018 ◽

Vol 148 (2) ◽

pp. 275-280 ◽

Cited By ~ 14

Author(s):

C.A. Hamilton ◽

A. Miller ◽

Y. Casablanca ◽

N.S. Horowitz ◽

B. Rungruang ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Oncology Group ◽

Ancillary Data ◽

Clinicopathologic Characteristics ◽

Term Survival ◽

Clinically meaningful quality-of-life changes in ovarian cancer: Results from gynecologic oncology group clinical trial 152

Clinical Therapeutics ◽

10.1016/s0149-2918(03)80262-x ◽

2003 ◽

Vol 25 ◽

pp. D26-D27

Author(s):

Lari Wenzel ◽

Bradley Monk ◽

Helen Huang ◽

David Cella ◽

Peter Rose

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Clinical Trial ◽

Gynecologic Oncology ◽

Life Changes ◽

Oncology Group

A Comparison of Quality-of-Life Domains and Clinical Factors in Ovarian Cancer Patients: A Gynecologic Oncology Group Study

Journal of Pain and Symptom Management ◽

10.1016/j.jpainsymman.2009.09.022 ◽

2010 ◽

Vol 39 (5) ◽

pp. 839-846 ◽

Cited By ~ 25

Author(s):

Vivian E. von Gruenigen ◽

Helen Q. Huang ◽

Karen M. Gil ◽

Heidi E. Gibbons ◽

Bradley J. Monk ◽

...

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Cancer Patients ◽

Gynecologic Oncology ◽

Life Domains ◽

Oncology Group ◽

Clinical Factors ◽

Oncology Group Study

The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.11.032 ◽

2012 ◽

Vol 124 (3) ◽

pp. 379-382 ◽

Cited By ~ 32

Author(s):

Vivian E. von Gruenigen ◽

Helen Q. Huang ◽

Karen M. Gil ◽

Heidi E. Frasure ◽

Deborah K. Armstrong ◽

...

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Overall Survival ◽

Adjuvant Chemotherapy ◽

Gynecologic Oncology ◽

Life Domains ◽

Oncology Group ◽

Oncology Group Study

Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2007.03.021 ◽

2007 ◽

Vol 106 (1) ◽

pp. 221-232 ◽

Cited By ~ 32

Author(s):

Angeles Alvarez Secord ◽

Kathleen M. Darcy ◽

Alan Hutson ◽

Paula S. Lee ◽

Laura J. Havrilesky ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Angiogenic Markers ◽

A cost–utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2014.10.020 ◽

2015 ◽

Vol 136 (2) ◽

pp. 293-299 ◽

Cited By ~ 18

Author(s):

David E. Cohn ◽

Jason C. Barnett ◽

Lari Wenzel ◽

Bradley J. Monk ◽

Robert A. Burger ◽

...

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Economic Model ◽

Gynecologic Oncology ◽

Cost Utility ◽

Cost Utility Analysis ◽

Oncology Group ◽

Utility Analysis